Janux Therapeutics JANX 深 滬
等待開盤 09-24 09:30:00 美东时间
16.52
-0.950
-5.44%
華盛通- 最 高17.47
- 今 開17.40
- 成交量 96.75万股
- 最 低 16.345
- 昨 收 17.47
- 總市值 10.10亿
- 52周最高 35.34
- 市盈率 靜 --
- 換手率 1.58%
- 52周最低 12.12
- 委 比 83.79%
- 總股本 6113.68万
- 歷史最高 71.71
- 量 比 0.80
- 振 幅 6.44%
- 歷史最低 5.65
- 每 手 1
- 風險率 5.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Janux Therapeutics Doses First Patient In The Phase 1 Clinical Trial For JANX013, Its PSMA-Targeted Tumor-Activated CD28 Co-Stimulatory Bispecific, In Patients With Metastatic Castration-Resistant Prostate Cancer
The program is initially being developed in combination with JANX007, with the goal of further enhancing the durability of anti-tumor immune responses through tumor-restricted CD28 co-stimulation. Over time, Janux intends to evaluate JANX013 in combination with additional candidates within its prost...
09-14 20:07
美股大行评级 | 首予买入！Jersey Mike's获13家大行评级；大摩、富国银行齐上调迈威尔科技目标价，最高升至310美元
今日重点评级关注：Truist Securities：维持CoreWeave"买入"评级，目标价从155美元升至165美元；百德：维持亚德诺"跑赢大市"评级，目标价从450美元升至675美元
08-25 11:47
This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst Chris O’Cull upgraded Darden Restaurants Inc (NYSE:DRI) from Neutral to Outperform ...
08-24 23:44
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target
Wolfe Research analyst Kalpit Patel upgrades Janux Therapeutics (NASDAQ:JANX) from Peer Perform to Outperform and announces $23 price target.
08-24 20:17
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55
Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $58 to $55.
08-08 01:00
财报速睇 | Janux Therapeutics 2026财年Q2营收0.10亿美元，去年同期为0；归母净利润亏损0.22亿美元，同比亏损缩窄35.1%
华盛资讯8月7日讯，Janux Therapeutics公布2026财年Q2业绩，公司Q2营收0.10亿美元，去年同期为0，归母净利润亏损0.22亿美元，同比亏损缩窄35.1%。
08-07 08:21
财报速睇 | Janux Therapeutics 2026财年Q2营收0.10亿美元，去年同期无营收；归母净利润亏损0.22亿美元，同比亏损缩窄35.3%
华盛资讯8月7日讯，Janux Therapeutics公布2026财年Q2业绩，公司Q2营收0.10亿美元，去年同期无营收，归母净利润亏损0.22亿美元，同比亏损缩窄35.3%。
08-07 07:42
Janux Therapeutics Q2 EPS $(0.35) Beats $(0.38) Estimate, Sales $10.267M Miss $16.493M Estimate
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 36.36 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $10.267 mill...
08-07 06:06
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
